Abstract
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have